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Abstract
Objective: To evaluate outcomes in prostate cancer patients classified as high-risk (HR) or very high-risk (VHR) who
were treated with conformal radiation therapy (CRT) and androgen deprivation therapy (ADT).
Methods: Between 11/2001 and 3/2012, 203 patients with HR disease received CRT to the prostate (78–82 Gy) and
pelvic lymph nodes (46–50 Gy) with ADT (6 m-2 years). Median follow-up was 50 months (12 m-142 m).
Biochemical failure was defined according to Phoenix definition. Imaging studies were used to identify local,
regional or metastatic failure. Four different VHR/HR groupings were formed using the 2014 and revised 2015
NCCN guidelines. Differences were examined using Kaplan Meier (KM) estimates with log rank test and uni- and
multivariate Cox regression analysis (MVA).
Results: Failure occurred in 30/203 patients (15%). Median time to failure was 30 m (4 m-76 m). KM estimate of
4 year biochemical disease free survival (b-DFS) for the entire cohort was 87% (95%CI: 82–92%). Four year KM
survival estimates for b-DFS, PCSS and OS were comparable for each NCCN subgroup. On univariate analysis, the
NCCN subgroups were not predictive of b-DFS at 4 years, however, DMFS was worse for both VHR subgroups
(p = .03and .01) respectively. Cox univariate analysis was also significant for: PSA ≥40 ng/ml p = 0.001; clinical stages
T2c p = .004, T3b p = .02 and > 4 cores with Gleason score 8–10 p < .03. On MVA, only PSA ≥ 40 ng/ml was
predictive for b-DFS or MFS at 4 years (HR: 3.75 and 3.25, p < 0.005).
Conclusion: Patients with HR and VHR disease treated with CRT and ADT had good outcomes. Stratification into
HR and VHR sub-groups provided no predictive value. Only PSA ≥40 ng/ml predicted poor outcomes on MVA.
Distant failure was dominant and local recurrence rare, suggesting that improved systemic treatment rather than
intensification of local therapy is needed.
Summary: Patients with high-risk prostate cancer are most often treated with conformal dose escalated radiation
therapy with androgen deprivation. Stratification into high versus very high-risk subgroups using 2014 or revised
2015 National Comprehensive Cancer Network (NCCN) criteria did not impact treatment outcomes. Only Prostate
Serum Antigen (PSA) ≥40 ng/ml was predictive of poor prognosis. Distant failure was dominant and local
recurrence uncommon which challenges the notion that intensification of local therapy will further improve
outcomes in patients with high-risk disease.
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Introduction
Physicians and patients, when asked about therapy for
localized prostate cancer often look to the National
Comprehensive Cancer Network (NCCN) guidelines to
provide guidance for selection between different treat-
ment options [1]. Since patients with high-risk (HR)
disease have a heterogeneous prognosis, this group has
been further subdivided to separate patients thought to
have the worst prognosis into the very high-risk (VHR)
category [1].
Radiation therapy (RT) has long been considered the pri-
mary treatment modality for patients with HR disease and
is the only treatment considered by the National Compre-
hensive Cancer Network (NCCN) to have sufficient evi-
dence to support a Category 1 treatment recommendation
[1]. Despite the NCCN treatment recommendations based
on improved outcomes for HR patients treated with high
dose conformal radiation therapy (CRT) and androgen
deprivation therapy (ADT), there is growing interest in the
use of radical prostatectomy (RP) for patients with HR dis-
ease [2, 3]. Justifications given for considering surgery are
high rates of local and systemic failure associated with the
use of RT as well as reported good outcomes associated
with the use of surgery [2, 3].
Sundi et al. defined a VHR group with adverse prog-
nostic factors predictive for poor outcome following sur-
gery and suggested the need for multimodal therapy to
improve outcomes [4, 5]. In consideration of these find-
ings, the 2014 NCCN guidelines were revised and added
the presence of primary Gleason grade 5 or ≥5 cores
with Gleason score 8–10 as new criteria for inclusion
into the VHR group [1]. While relevant for surgical out-
comes, the predictive value of the HR/VHR grouping
has not been assessed in patients treated with current
CRT techniques [6]. Recently, Narang et al. showed
inferior outcomes in the VHR versus HR group in a
cohort of patients treated with RT and ADT from 1993
through 2006. However, this retrospective study was
limited by use of radiation techniques, treatment vol-
umes, dose, and use of ADT that do not reflect current
therapeutic approaches [6].
We reviewed treatment outcomes in a cohort of patients
with HR disease treated with high dose CRT and ADT to
determine if local recurrence (LR) or metastatic disease
was predominant. Patients were stratified according to the
original and revised NCCN guidelines for HR/VHR
groups. The value of this classification system to provide
prognostic guidance and improved treatment recommen-
dations for patients with HR disease was assessed.
Methods
Patients
The radiation oncology prostate cancer database of 509
patients entered between November 2001 and March
2012 was reviewed following approval of the hospital
ethics committee. Patients meeting NCCN criteria for
HR or VHR disease (n = 203) who were treated with
CRT were identified. Demographic information, clinical
stage, PSA, Gleason grade and score, number and
percentage of biopsy cores involved with tumor, use of
ADT, and early and late treatment toxicity data were
extracted from the electronic medical record. Treatment
technique, radiation dose, fraction schedule, target vol-
ume and use of image guidance were obtained from the
treatment planning system.
The characteristics and treatments of these 203 HR
patients are listed in Table 1. Median age was 74 years
(range 56 years-89 years). Gleason scores were > 7 in 143
patients and ≤7 in 60 patients. Primary Gleason grade 5
and Gleason score 8–10 in ≥ 5 cores occurred in 17 pa-
tients and 82 patients respectively. Median PSA was
15.1 ng/ml (range: 1.4 ng/ml– 449 ng/ml). PSA level was
≥40 ng/ml in 33 patients and < 40 ng/ml in 170 patients.
Clinical stage was ≤ T2b in 85 patients, T2c in 19 pa-
tients, T3a in 62 patients and ≥ T3b in 37 patients. Al-
most half of the cohort had ≥ stage T3 disease.
NCCN Risk group stratification
The study population included all patients with clinical
stage ≥T3a, or Gleason score ≥8, or PSA > 20 ng/ml.
These patients were sorted according to the NCCN
definitions of HR and VHR using the original or revised
criteria for VHR: (≥ T3B) or (≥T3b or primary Gleason 5
or ≥ 5 cores with Gleason 8–10). Since patients with ≥ 2
HR factors present may be considered as either HR or
VHR, and this upstaging is not applied universally, the
original and revised NCCN groups were each consid-
ered ± upstaging for patients with ≥2 HR factors. The 4
different HR/ VHR groupings created using NCCN
criteria were compared.
Planning and treatment guidelines
All patients received high dose CRT to the prostate and
seminal vesicles, pelvic lymph node RT (PLNRT) and
ADT. Contouring and planning guidelines evolved over
time and guidelines in current use are described below.
Prostate and Seminal Vesicles: The prostate was con-
toured on axial images from the treatment planning CT
scan. The entire seminal vesicles were contoured separ-
ately. The prostate and seminal vesicles were combined
to create the CTV and then expanded 1 cm in all direc-
tions except for 0.7 cm posteriorly to create the PTV.
The PTV and CTV were planned to 95 and 98% of the
prescribed dose respectively. Three treatment protocols
were used for treatment: From 2001 to 2009, 30 patients
received 3D CRT to 78Gy-82Gy at 2 Gy/fx; from 2004
to 2011, 72 patients received IMRT to 78Gy-82Gy at
2 Gy/fx, and from 2010 to 2012, 101 patients received
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VMAT and hypo-fractionation to 73.6Gy at 2.3Gy/fx
(80Gy 2gy/eq., σ/β = 1.5). Image guided radiation therapy
(IGRT) was introduced into the clinic in 2009 and daily
on-line correction was performed daily for all patients [7].
PLNRT
Pelvic lymph nodes were identified by contouring and
expanding by 7 mm the distal common iliac vessels
and external iliac vessels from L5/S1 to the femoral
head and symphysis pubis, carving out bowel, bladder
and bone. PLNRT was given at 46 Gy at 2Gy/fx.
After 2011, PLNRT was given at 54.4 Gy at 1.7 Gy/fx
(50Gy 2 Gy/eq, α/β = 1.5). All but 2 patients received
PLNRT.
Organs at risk
The bladder, rectum from anus to sacral promontory,
loops of bowel and femoral heads were contoured.
Small bowel dose was limited to 54 Gy with no more
than 2 cc receiving 50 Gy. Rectal dose was limited to
V75 < 15%, V70 < 25% and V50 < 50%. Bladder dose
was V80 < 15%, V75 25%, V65 < 65% and femoral head
dose was < 40Gy.
ADT
ADT was prescribed for 6 months-3 years. ADT dur-
ation: ≤ 6 months n = 14 (7%); >6 months- <24 months
n = 9 (4.4%); ≥24 months n = 174 (86%). Six patients (3%)
received no ADT and 1 of these did not receive PLNRT.
Follow up
Median follow-up for the entire cohort was 50 months
(m) (range: 12 m-142 m). Follow-up evaluations follow-
ing CRT were performed at intervals of 6 m to 1 year.
Patients who did not appear for follow-up were con-
tacted telephonically and PSA results were obtained
from the electronic medical record.
Biochemical recurrence (BR): When BR was detected,
patients underwent diagnostic evaluation with bone scan
and CT scans. If the site of recurrence was not identi-
fied, patients were offered imaging with choline PET-CT
or endorectal MRI (e-MRI), [8]. ADT was not started
unless metastatic disease was found. Patients with local,
regional, or oligo-metastatic recurrence were offered
focal radiation therapy with short term ADT at the dis-
cretion of the treating physician.
Table 1 Patient characteristics
Parameter All patients Patient’s with
biochemical failure
N=203 % N=30 %
Age (year)
Median (range) 75 (56–89) - 74.5 (56–86) -
Clinical stage
T1-T2a 39 19.2 3 10
T2b-c 65 32 10 33.3
T3a 62 30.5 9 30
T3b-T4 37 18.3 8 26.7
Gleason score
≤ 6 15 7.4 1 3.3
7 45 21.2 8 26.7
8–10 143 70.4 21 70
PSA
Median (range) 16 (1.4–449) - 22.7 (1.4–449) -
<10 71 35 8 26.66
10–20 48 23.6 6 20
20.1–39.9 51 25.1 5 16.66
≥40 33 16.3 11 36.66
>4 cores positive with Gleason 8–10
≤4 109 53.7 12 40
>4 82 40.4 17 56.7
Unknown 12 5.9 1 3.3
Primary Gleason pattern
<5 186 91.6 25 83.3
5 17 8.4 5 16.7
NCCN risk group
High risk 100 49.3 11 36.7
VHR 103 50.7 19 63.3
RT technique
3D 29 14.3 6 20
IMRT 60 29.6 11 36.7
VMAT 114 56.1 13 43.3
ADT use
Yes 197 97 28 93.3
No 6 3 2 6.66
Duration ≤ 6 mo 14 6.9 0 0
Duration 6–24 mo 9 4.4 2 6.66
Duration ≥ 24 mo 174 85.7 26 86.66
Prostate radiation dose
<78 Gy 2 Gy/fx. 5 2.5 1 3.3
78–82 Gy 2 Gy/fx 97 47.8 18 60
73.6 Gy 2.3 Gy/fx 101 49.7 11 36.7
Table 1 Patient characteristics (Continued)
Pelvic lymph node RT
Yes 201 99 30 100
No 2 1 0 0
46 Gy 88 43.3 16 53.3
54.4 Gy 113 55.7 14 46.7
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Endpoints
Endpoints used include biochemical disease free survival
(b-DFS), (Phoenix definition) [9], distant metastasis free
survival (DMFS), prostate cancer specific survival (PCSS)
and overall survival (OS). Toxicity and side effects were
recorded using CTCAE version 4 [10].
Statistics
Statistical analysis was performed using STATA. Con-
tinuous and categorical variables were compared using a
two-tailed Students t-test or Chi-squared test res-
pectively. The Kaplan-Meier (KM) method was used to
calculate probability of survival and toxicity. Cox univar-
iate analysis was conducted using log-rank tests and
univariate predictors with a p-value <0.2 were further
considered using a Cox multivariate proportional haz-
ards model (MVA) to identify predictors of gastroin-
testinal (GI) or genitourinary (GU) toxicity and survival.
P values ≤ .05 were considered significant.
Results
Failure occurred in 30/203(15%) patients. Median time
to failure was 30 m (range: 4 m-76 m). Failures were
classified as BR only (n = 4), local (n = 1) or metastatic
(n = 25). Table 2 lists the sites of failure. In 8 patients
who were initially classified as BR, the use of choline
PET-CT imaging showed the location and extent of
recurrence. Prostate cancer specific mortality was re-
corded in 4 patients. Eleven deaths were unrelated to
prostate cancer.
Four different NCCN HR/VHR groupings were evalu-
ated. Patients shifted from the HR group to the VHR
group as definitions evolved and additional risk features
were included (Table 3). The size of the VHR group
increased from 18 to 68% of the patients and HR group
decreased from 82 to 32%.
KM estimate of 4 year b-DFS for the entire cohort was
87% (95%CI: 82–92%). The 4 year KM survival estimates
for b-DFS, CSS and OS were comparable for each of the
NCCN subgroups (Table 3) and this was confirmed by
Cox regression. On univariate analysis, the NCCN
subgroups were not predictive of b-DFS at 4 years. Only
DMFS was worse for the VHR group for both pre and
post revision NCCN definitions (p = .03 and .01 respect-
ively). This difference was not observed if upstaging using
≥2HR factors was applied and this effect did not persevere
on MVA. Cox univariate analysis was also significant for:
PSA ≥40 p = 0.001; clinical stages T2c p = .004, T3b p = .02
and > 4 cores with Gleason 8–10 p < .03.
On MVA, PSA ≥ 40 ng/ml was the only significant pre-
dictor of b-DFS or DMFS at 4 years with a HR of 3.75
and 3.25, p < 0.005 (Table 4). KM estimates for PSA
above and below 40 ng/ml are shown in Figs. 1a and b.
Treatment was well tolerated with significant late ≥
grade 3 GU toxicity of 10% which was predominantly
due to reports of nocturia more than 5 times per night.
Late ≥ grade 3 GI toxicity of 3.5% was due to rectal
bleeding (Table 5).
Discussion
This study supports the assertion that patients with both
HR and VHR prostate cancer treated with high dose
CRT, PLNRT and ADT have favorable outcomes with
low toxicity. The use of dose escalation, CRT, PLNRT,
image guidance and ADT have all been associated with
improved outcomes or reduced toxicity [11–15] and the
results of this study are consistent with favorable out-
comes reported from studies that used CRT with ADT
to treat patients with HR disease [16]. While our results
are encouraging, these findings must be interpreted
cautiously since longer follow-up time is needed to verify
our findings.
Dissimilarities in risk factors and co-morbidities of HR
patients treated with RP or CRT make comparison of
outcomes between surgical and radiation treatments
unreliable. Series reporting treatment outcomes for CRT
with HR disease include many patients with advanced
disease or comorbidities that would exclude consider-
ation for RP. Despite the inclusion of patients with
adverse risk factors, our results compare well to outcomes
reported for HR patients treated with RP [2, 17, 18].
Furthermore, we report low rates of acute and late GI and
GU toxicity that are consistent with other CRT series
[19]. In contrast, HR patients treated with RP often
require adjuvant or salvage RT which is associated
with increased toxicity when compared to treatment
with RP or RT alone [20, 21].
The 2015 revisions to the VHR subgroup were based
on the findings of Sundi et al. who reviewed prognostic
factors and outcomes from a surgical series of 753 men
with HR prostate cancer to create risk factor groupings
predictive for metastatic disease and prostate cancer
specific mortality [4]. Based on Sundi’s findings, the
revised 2015 NCCN guidelines added two additional
criteria for inclusion of HR patients into the VHR sub-
group [1, 4]. When subdividing our CRT series into HR/
VHR subgroupings, we observed that stage migration
Table 2 Sites of Recurrence
0 173 85.2
Biochemical failure 4 2
M1a 3 1.5 2
M1b 16 7.9 4
M1c 6 3 1
Local 1 0.5 1
M1a = non regional lymph nodes, M1b =bones, M1c = visceral
When several sites of recurrence were present, the most advanced category
was used
Saad et al. Radiation Oncology  (2017) 12:5 Page 4 of 8
was substantial. The percentage of patients considered
VHR increased from 18 to 62% as the number of criteria
considered for inclusion in the VHR subgroup increased.
We suggest that redistribution of patients into the VHR
group may improve the reliability of comparisons of HR
patients treated primarily with surgery versus those
treated with radiation.
We found that patients treated with high dose CRT
and ADT did well irrespective of current HR/VHR
classification and that PSA ≥40 ng/ml was the best dis-
criminator of poor outcomes. In contrast to our findings,
Narang et al. showed that when evaluating patients with
HR disease who were treated over a 15 year interval
from 1993 to 2006, the revised 2015 NCCN HR/VHR
subgrouping were predictive for worse outcomes in the
VHR subgroup [6]. Although the long follow-up interval
is an important strength of Narang’s study, the median
follow-up time of our cohort is 50 m (range: 12 m-142 m)
and the median time to BF in our reports are similar at
34 m and 30 m. The difference in our findings may be
better explained by the differences in treatment received
by our respective cohorts. Narang reported the use of a
diverse assortment of radiation techniques with a mean
dose of 70.2 Gy (range: 64.8–75.6 Gy), and differing ADT
protocols. Narang was unable to demonstrate improve-
ment in failure endpoints with dose escalation over 72Gy
although use of neo-adjuvant ADT was associated with
reduced BF and DMFS. In comparison, the patients in our
series received uniform CRT with a minimum dose of
78 Gy (range: 78–82 Gy), PLNRT, and ADT that is
reflective of current practice. Increased radiation dose
and use of ADT have been shown to be associated
with improved b-DFS and DMFS [11, 22, 23]. Pollack
et al. in a randomized trial showed that doses <78 Gy
versus ≥ 78 Gy were associated with improved b-DFS
and DMFS and Denham et al. reported that both
dose escalation and increased duration of ADT re-
duced local progression and BF [22, 23].
The only risk factor predictive for reduced b-DFS or
DMFS on MVA in our series was PSA ≥40 ng/ml. This
finding is consistent with other studies showing elevated
PSA at time of diagnosis to be highly predictive for
metastatic disease following either RT or RP [24–27].
These findings suggest that future modifications to the
NCCN guidelines consider PSA level as a criteria for
Table 3 Patient distribution by NCCN HR and VHR risk groups and 4 year b-DFS, MFS, CSS and OS
2014 2014+>2 HR 2015 2015+>2 HR
HR VHR HR VHR HR VHR HR VHR
N 166 37 131 72 100 103 65 138
% 82% 18% 64.5% 35.5% 49% 51% 32% 68%
4y bDFS % (95% CI) 89 (82–93) 83 (66–92) 89 (82–93) 84 (73–91) 90 (82–95) 85 (75–91) 92 (80–97) 85 (78–90)
4y MFS % (95% CI) 90 (84–94) 83 (63–93) 92 (84–96) 85 (72–92) 93 (85–97) 85 (75–92) 93 (78–98) 87 (80–92)
4y CSS % (95% CI) 100 92 (70–98) 100 95 (82–99) 100 97 (88–99) 100 98 (91–99)
4y OS % (95% CI) 96 (92–99) 85 (64–94) 98 (93–100) 87 (74–94) 96 (89–99) 92 (83–96) 100 91 (84–96)
HR = High Risk, VHR = Very High Risk, b-DFS = biochemical disease free survival, MFS = metastasis free survival, CSS = cause specific survival, OS = overall survival
NCCN 2014 HR= Stage: T3a, Gleason: 8–10, PSA>20, VHR= T3B, T4
NCCN 2015 HR= Stage: T3a, Gleason: 8–10, PSA>20, T3b-T4, Primary Gl 5, >4 cores with Gl 8–10
Table 4 Univariate and Multivariate Survival Analysis
Variable Univariate analysis Multivariate analysis
P-value HR (95% CI) P-value HR (95% CI)
Clinical stage
T1-T2a - 1.0 (reference) - -
T2b-c 0.162 2.51 (0.69–9.16) - -
T3a 0.227 2.23 (0.6–8.28) - -
T3b-T4 0.045 3.91 (1.02–14.86) 0.138 1.33 (0.91–1.93)
Gleason score
≤ 6 - 1.0 (reference) - -
7 0.223 3.65 (0.45–29.42) - -
8–10 0.34 2.66 (0.35–19.87) - -
PSA
<40 - 1.0 (reference) - -
≥40 <0.001 3.84 (1.82–8.080 0.001 3.75 (1.76–7.97)
>4 cores positive with Gleason 8–10
≤4 - 1.0 (reference) - -
>4 0.032 2.27 (1.07–4.8) 0.23 1.41 (0.8–2.51)
Unknown 0.635 0.6 (0.07–4.7) - -
Primary Gleason pattern
<5 - 1.0 (reference) - -
5 0.124 2.12 (0.81–5.55) - -
NCCN risk
High risk - 1.0 (reference) - -
VHR 0.07 1.99 (0.94–4.23) - -
RT technique
3D - 1.0 (reference) - -
IMRT 0.392 1.57 (0.55–4.41) - -
VMAT 0.376 1.67 (0.53–5.22) - -
Saad et al. Radiation Oncology  (2017) 12:5 Page 5 of 8
inclusion into the VHR group. We caution that elevated
PSA should not be used as an exclusion criteria for
definitive treatment since many patients with elevated
PSA may benefit from definitive therapy [24].
Patterns of failure analysis shows that distant failure
was dominant and isolated initial failure within the
lymph nodes, prostate or as BF alone was uncommon.
The use of functional imaging has allowed us to identify
sites of distant failure early which decreased the number
of patients considered LR or BF alone. In contrast to our
findings, several studies which used bone scan, CT
and prostate biopsy to evaluate patients with BF have
reported that the prostate is the most common first
site of failure following RT for HR patients [28, 29].
Although prostate biopsy results were not available in our
series, choline PET-CT and endorectal-MRI imaging in
patients with BF allowed for early detection of metastatic
disease in most patients. These findings support the use of
CRT with ADT to treat patients with HR disease and
suggest that further intensification of local therapy will
provide little benefit for HR patients and may only add
morbidity. [2, 3, 17, 30, 31].
The NCCN guidelines were revised in 2014 to include
choline PET-CT imaging of patients with BF for consid-
eration of focal salvage therapy [32]. Early adaptation of
functional imaging with choline PET-CT allowed us to
offer patients with local failure or oligo-metastatic
disease salvage treatment using targeted radiation ther-
apy and avoid early administration of ADT [8]. Extend-
ing the use of functional imaging agents for use during
initial staging may further improve outcomes with RP
and CRT by identifying and excluding patients with early
metastatic disease from receiving definitive therapy.
The absence of a central pathology review is an im-
portant study limitation. Since patients were referred
from several different institutions, variation between
pathologists in assigning Gleason grades to the biopsy
specimens may have affected the classification of our
patients into HR and VHR subgroups. Although several
different CRT treatment techniques were used during
the study period and moderate hypo-fractionation and
IGRT were instituted only after 2009, univariate and multi-
variate analysis were unable to demonstrate differences in
outcome based on treatment technique. Although most
BFs occur within 5 years of treatment [33], longer duration
of follow-up is needed to verify our findings.
Conclusions
Prostate cancer patients with HR and VHR disease
achieve excellent LC and DMFS with low toxicity when
treated with dose escalated CRT, PLNRT and ADT.
Reclassification of HR patients into HR/VHR subgroups
using original or revised NCCN criteria had no impact
on treatment outcomes. Only PSA ≥40 ng/ml was
associated with poor prognosis. The use of functional
imaging to evaluate BF showed that distant failure was
dominant and LR in the prostate rare, challenging the
notion that intensification of local therapy will further
improve outcomes. Further study and longer follow-up
is required to validate these findings.
Fig. 1 a and b KM Survival Estimate Stratified by PSA≥ 40 ng/ml, <40 ng/ml showing Biochemical Disease Free Survival (Fig. 1a) and Metastasis
Free Survival (Fig. 1b)
Table 5 Toxicity Profile
GI toxicity GU toxicity
Acute (%) Late (%) Acute (%) Late (%)
Grade 0 140 (69%) 166 (82%) 53 (26%) 117 (58%)
Grade 1 58 (29%) 17 (8%) 112 (55%) 31 (15%)
Grade 2 3 (1.5%) 13 (6.4%) 32 (16%) 34 (17%)
Grade 3 2 (1%) 7 (3.5%) 6 (3%) 21 (10%)
Grade 4 - - - -
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